Inovio Pharmaceuticals Investors Face Deadline in Securities Class Action
Investors who purchased Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, may be eligible to participate in a securities class action lawsuit. A lead plaintiff deadline of April 7, 2026, has been set for those wishing to seize a leadership role in the litigation.
What’s at Stake? Allegations of Misleading Statements
The lawsuit alleges that Inovio Pharmaceuticals made false and/or misleading statements concerning the manufacturing of its CELLECTRA device and the timeline for submitting the INO-3107 Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). Specifically, the suit claims the company lacked sufficient information to support claims regarding FDA accelerated approval or priority review, ultimately overstating the regulatory and commercial prospects of INO-3107.
Who is Rosen Law Firm?
Rosen Law Firm, a global investor rights law firm, is leading the charge in this case. The firm encourages investors to secure legal counsel before the April 7th deadline. Rosen Law Firm highlights its experience in securities class actions and shareholder derivative litigation, noting its track record of success, including achieving the largest ever securities class action settlement against a Chinese Company and being ranked among the top firms by ISS Securities Class Action Services.
Contingency Fee Arrangement: No Upfront Costs
Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without incurring any out-of-pocket fees or costs. The arrangement operates on a contingency fee basis, meaning legal fees are only paid if a recovery is obtained.
The Role of a Lead Plaintiff
The court must select a lead plaintiff to represent the interests of all class members. This individual or entity will be responsible for directing the litigation. Investors interested in serving as lead plaintiff must file a motion with the Court by April 7, 2026.
Why Choose Experienced Counsel?
Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions. The firm cautions investors to be wary of firms that act as “middlemen,” simply referring cases to other firms without directly handling the litigation. They highlight their global reach and concentration on complex securities litigation.
Navigating Securities Class Actions: A Growing Trend
Securities class action lawsuits are becoming increasingly common as investors seek redress for financial losses resulting from alleged corporate misconduct. These cases often involve complex financial instruments and require specialized legal expertise. The Inovio Pharmaceuticals case is part of a broader trend of investor litigation targeting pharmaceutical and biotechnology companies.
Did you know?
In 2019, Rosen Law Firm secured over $438 million for investors. Founding partner Laurence Rosen was named a Titan of Plaintiffs’ Bar by Law360 in 2020.
What Should Investors Do?
If you purchased Inovio Pharmaceuticals (INO) securities between October 10, 2023, and December 26, 2025, you have several options:
- Join the class action: Submit your information through the Rosen Law Firm website.
- Seek lead plaintiff status: File a motion with the Court by April 7, 2026.
- Remain an absent class member: Do nothing at this time.
- Retain your own counsel: You have the right to choose your own legal representation.
FAQ
Q: What is a securities class action?
A: A lawsuit filed on behalf of a group of investors who have suffered similar losses due to alleged fraudulent or misleading practices by a company.
Q: What is the deadline to join the Inovio Pharmaceuticals class action?
A: The lead plaintiff deadline is April 7, 2026.
Q: What does it signify to be a lead plaintiff?
A: A lead plaintiff represents the interests of all class members and directs the litigation.
Q: Will I have to pay anything upfront to join the lawsuit?
A: No, the lawsuit is being handled on a contingency fee basis, meaning you will only pay if a recovery is obtained.
Resources
- Rosen Law Firm – Inovio Pharmaceuticals Class Action
- Rosen Law Firm LinkedIn
- Rosen Law Firm Twitter
- Rosen Law Firm Facebook
To learn more about your legal options, contact Phillip Kim, Esq., toll-free at 866-767-3653 or via email at [email protected].
